

Index

- acute flaccid paralysis (AFP)
 - 18–20, 26, 30
- adenoviruses 48–9, 129, 132,
 - 134–5, 139–40, 396
 - human 132, 139
- aerosols 42–4
- AFENET, *see* African Field Epidemiology Network
- affinity 117, 175, 313, 315, 353, 385–8, 460–1
- affinity biosensors 461
- AFM, *see* atomic force microscope
- AFP, *see* acute flaccid paralysis
- African Field Epidemiology Network (AFENET) 433
- African wild dogs 231
- AIVs, *see* avian influenza viruses
- aluminum 204, 206, 213–16, 220
- amperometric biosensors 454,
 - 465–6, 468–9, 474
- amperometric detection 465,
 - 476–7
 - pulsed 473
- amperometric enzyme biosensors 461, 463, 465, 467
- amperometric immunosensor 320, 481–3
- amperometry 456–8, 462–5, 470, 472, 483
- amplicons 259, 411, 415–17, 419
- anthrax 41, 201–2
- anti-DEN IgM antibodies 367–8
- anti-OROV IgM antibodies 84–5
- antibodies 54, 175–6, 178, 184–5, 314, 318–19, 338, 357–8, 365, 370, 386–7, 400–1, 460–1, 469, 479–82
 - antiviral 158, 282
 - biotinylated 361
 - detection of 54, 180, 241, 336, 369
 - secondary peroxidase-labeled 477
- antigen detection 157–9, 181
 - included virus 431
- antigen detection assays 136
- antigenic shift 99, 106–7, 121, 130
- antigens 158, 160, 173, 178–9, 234, 238, 314–15, 318–19, 338, 421, 465, 469, 472, 474, 481
- aptamers 186, 385–91
 - anti-influenza 394
 - oligonucleotide 385–7, 390–1
- assays
 - cell-based 164
 - diagnostic 257–8
 - microwave-accelerated 210
- asymptomatic H5N1 Infections 107, 110–11
- atomic force microscope (AFM) 205–6, 337–8, 376
- avian influenza 110
- avian influenza subtype H5N1 97–8, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122

- avian influenza virus H5N1 129, 140
- avian influenza viruses (AIVs) 101–2, 120
- bacteria 40–1, 254, 258, 263, 265, 268, 281–2, 302, 308, 310, 313, 374–5, 460–1, 479, 484
infected 303, 305
- bacterial infections 281, 283, 285–6, 288–9, 454
- bacteriophages 301–2, 310, 316, 318, 477
- bats 231–2, 234, 403
- BIDSS, *see* Border Infectious Disease Surveillance system
- bioassay platform technology 220
- bioassays, fluorescence-based 206
- biochips 183, 321, 334–5, 339
- bioerror 17–21, 29–30
- bioreceptor Immobilization 353, 355, 357, 359, 361
- biorecognition molecules 460–1
- biosensors 181, 183, 185, 321, 344–6, 353, 356, 359, 362–5, 370, 376, 460–1, 465–7, 475, 478
arrayed 334
catalytic 460–1
development of 164, 344
optical 344, 346
- bioterror 17–21, 29–30
- biothreat agents 188, 343–4
- biotin 255, 359–61, 370, 372
- bioweapon potential of
filoviruses 40–1, 43, 45, 47, 49, 51, 53
- birds 2, 5, 97–9, 101–4, 106–7, 109–11, 116, 120, 122, 474, 483
infected 120, 318, 483
- blood 41, 54, 80, 88, 171, 175, 273, 275, 280, 286, 435, 441, 472, 482, 484
- BLV, *see* bovine leukaemia virus—VSV
- Border Infectious Disease Surveillance system (BIDSS) 5
- bovine leukaemia virus—VSV (BLV) 402, 455, 459, 472–3
- bow-tie structures 214–16, 220
- capacity-effectiveness-velocity (CEV) 279
- capsid proteins 22, 29, 302, 311, 314, 316
- capsids 308–9
- CCHF, *see* Crimean-Congo hemorrhagic fever
- CCHF virus 257–9
- cell lines 53, 133–4, 156, 160
- cells
bacterial 305–6, 309, 316
dendritic 38–9
electrochemical 462–4
lymphocyte 186
mammalian 161
mouse spleen 282
phagocytic 264, 266, 269, 282
transduced 398, 400–1
- central nervous system (CNS) 8, 12, 40, 233–4, 413, 475
- CEV, *see* capacity-effectiveness-velocity
- CGD, *see* chronic granulomatous disease
- characterization 53, 55, 158, 174, 179, 205, 235, 240, 274, 300, 399, 402, 409, 451, 460
functional 400–1, 403
molecular 22–3
- chemiluminescence 143, 267, 345, 350–1, 365, 414

- chemiluminescence ELISA 367–8
 chemiluminescence reaction 350
 chemiluminescence signal 350,
 366, 368, 372
 chemiluminescent probe 274
 chromatographic assays 420–2
 chronic granulomatous disease
 (CGD) 281
 circulating phagocytes 277, 279,
 282, 290
 clinical microbiology laboratories
 141
 CNS, *see* central nervous system
 commercialization 65–6, 68, 70,
 72, 74–6, 377
 communicable disease outbreak
 11–12
 communicable diseases 3, 11–12
 conducting polymers 184, 468,
 470
 contamination 55, 136, 138,
 239–40
 Crimean-Congo hemorrhagic fever
 (CCHF) 151, 257, 259
Culicoides paraensis 82–3
 cytomegalovirus 134, 282, 402,
 413
- data mining 4, 281, 284, 289–90
 Dectin-1 271–2
 degranulation 272, 274, 280
 dengue 80, 183, 398
 dengue fever 74
 dengue virus 41, 183, 412, 484
 detection
 antibody 175, 241, 365
 nucleic acid 157, 173, 181, 370,
 421
 oligonucleotide 372
 detection of anti-DEN IgM
 antibodies 367
 detection of anti-OROV IgM
 antibodies and OROV
 genome 84
 detection of anti-West Nile virus
 IgG antibodies 365
 detection of biological threat
 agents 314
 detection of human pathogens
 253–60
 detection of lyssavirus RNA 239
 detection of negative-stranded
 RNA viruses 157
 detection of RABV antibodies 242
 detection of silent circulation of
 wild poliovirus 26
 detection of viruses 454, 461
 detection sensitivities 138, 182,
 320
 detection system development
 161, 164
 diagnosis of infectious diseases
 135, 411
 diagnostic facilities 228, 243
 diagnostic methods 128, 157–8,
 228, 230, 234, 239–41, 301
 diagnostic techniques 132–3, 135,
 137, 139, 141, 143
 diagnostics 65, 71–5, 132, 134–6,
 177, 179, 182–3, 185–8,
 227–8, 230, 232, 234, 385–6,
 388, 390
 molecular 403, 409–10, 418,
 420
 rapid 335, 443
 dip-pen nanolithography (DPN)
 183, 337–9
 disease monitoring 409–10
 DNA 212–13, 215–18, 220–1,
 306–7, 309, 311, 319, 334,
 336, 411, 414–15, 417, 459,
 461, 470–3
 release of 215–16
 DNA detection 319, 414

- DNA hybridization assays 211, 370
- DNA polymerase 310, 414–15, 418–19
- DNA replication 310–11, 411, 414–15
- DNA vaccination 48
- DNA vaccines 47–8
- DPN, *see* dip-pen nanolithography
- Ebola 150, 152, 157, 160, 169–76, 186–8, 412, 427–8, 437, 439, 441–3
- Ebola antigen detection 176, 180
- Ebola detection 177–8, 187–8
- Ebola diagnostics 179, 181, 187
- Ebola hemorrhagic fever (EHF) 169, 175–6, 181, 427, 429–30, 432–3
- Ebola hemorrhagic fever virus 169–70, 172, 174, 176, 178, 180, 182, 184, 186, 188
- Ebola infection 169, 171, 174, 176
- Ebola outbreaks 172, 177, 429, 435, 437–8
- Ebola virus 41, 71, 152, 169–70, 172, 177–8, 181, 186–8, 368, 402, 415, 428, 437, 439
strains of 179
- Ebola virus antibodies 181
- Ebola virus antigens 175, 181, 431
- Ebola virus infection 175
- EHF, *see* Ebola haemorrhagic fever
- ELAHA, *see* enzyme-linked amplicon hybridization assay
- electric field intensity 203–4, 213
- electric fields 201, 203, 213–14
- electrochemical detection 183, 421
- electrode surface 462, 465, 467–9, 477
graphite 478
- electrodes 368, 462–6, 468, 472, 480
reference 362, 462, 464
- electron microscopy 173–5, 188, 304
- electrons 267, 350–1, 363, 462, 468
- electropolymerization 359, 361–2, 368
- ELISA, *see* enzyme-linked immunosorbent assay
- encephalitis vaccine 475
- engineered recombinant proteins 177
- enteroviruses 17, 134
nonpolio 19, 21
- environmental surveillance 20–1, 26, 31
- environmental surveillance for polioviruses 17–18, 20, 22, 24, 26, 28, 30
- environmental surveillance program 20–1, 23, 30
- enzyme-linked amplicon hybridization assay (ELAHA) 139
- enzyme-linked immunosorbent assay (ELISA) 53–5, 172, 175–6, 179–80, 182, 185, 187, 238, 300, 318–19, 333, 415, 431, 433, 474
- enzymes 143, 161, 265–6, 270, 300, 312, 353, 370, 413, 415, 418, 460, 465–8, 470
- epidemics 36, 43, 80, 82, 108, 111, 130, 171, 187, 333, 428, 432–3, 437, 479, 483
- epidemiology 17, 86, 105, 107, 109, 170, 431
- epitopes 112–13, 314, 316–17
- exosporium 212–13, 215–17
- FAT, *see* fluorescent antibody test

- FAVN, *see* fluorescent antibody virus neutralization
- fever 8, 12, 71, 79, 111, 427, 429–30, 433–4, 438
- FHF, *see* filovirus hemorrhagic fever
- fiber optic biosensors 344
- filamentous bacteriophage 305
- filamentous phages 302–3, 305–8
- filovirus biology 37
- filovirus hemorrhagic fever (FHF) 43–6, 50, 53–4, 56
- filovirus infections 39, 45, 50–3
- filoviruses 35–54, 56, 170, 174, 428
- long incubation period of 44, 55
- first-line defense mechanism 265, 267, 269, 271, 273, 275
- fluorescent antibody 135, 158, 172, 227, 236, 241, 441
- fluorescent antibody test (FAT) 227, 234–9, 241–2
- fluorescent antibody virus neutralization (FAVN) 241
- fluoroimmunoassay, sandwich 352
- fluorophores 210–11, 220
- formyl peptide receptors (FPRs) 280
- FPRs, *see* formyl peptide receptors
- frugivorous bats 229
- gene expression 305–6, 310–11
- geographic information system (GIS) 5
- GIS, *see* geographic information system
- glass 204–6, 208–9, 212, 216, 219, 338–9, 347
- gold nanoparticles 421, 480
- HCV, *see* hepatitis C virus
- HCV infection 478
- HDA, *see* helicase-dependent amplification
- headache 12, 18, 39, 80, 431, 433–5
- helicase-dependent amplification (HDA) 411–12, 415, 420
- hemorrhagic fever 433, 435
- hepatitis 183, 390, 402, 413, 458, 477–9
- detection of 184, 481
- hepatitis C virus (HCV) 183, 368, 390, 402, 412–14, 419, 421, 459, 477–8
- herpes simplex virus (HSV) 134, 412–13
- high-throughput screening (HTS) 150, 162, 164, 207
- highly pathogenic avian influenza (HPAI) 97, 102–3, 111, 114, 402
- HIV, *see* human immunodeficiency virus
- HPA, *see* hybridization protection assay
- HPAI, *see* highly pathogenic avian influenza
- HSV, *see* herpes simplex virus
- HTS, *see* high-throughput screening
- human disease 104, 109, 111, 117, 443, 454
- human H5N1 disease 116, 121
- human immunodeficiency virus (HIV) 45, 65–6, 69, 183, 282, 316, 338, 365, 388, 396–8, 410, 412, 414, 421, 483
- human infections 229, 454
- human metapneumovirus 129, 413
- human neutrophils 280–2
- human papilloma virus 258
- human pathogens 98, 130, 253–60

- human population 84, 100, 107, 109, 111, 118, 120–1, 129, 131, 140, 144
- human respiratory epithelium 117
- human sera samples 318, 368–9
- hybridization 138, 140–1, 179, 212, 255–7, 260, 310, 371–2, 418, 470, 477
- hybridization protection assay (HPA) 414

- IAV, *see* influenza A virus
- ICSB, *see* ion channel switch biosensor
- IgG antibodies 53, 178, 365, 367–8, 441
- IgM antibodies 178, 365, 367–8, 441
- immune responses 40, 49–50, 157, 171, 173, 234, 264, 271, 316, 469
- immune system 130, 234, 264, 271, 279, 286, 288–9
- immunity 98, 107–8, 111, 113–14, 131
- immunoassays 135, 173, 175, 178, 350, 362, 364, 366, 369, 375, 410, 416, 461, 468, 471–2
 - direct 338–9
- inactivated poliovirus vaccine (IPV) 18–19, 21–2
- infection
 - common 438
 - productive 43, 234
- infection control 42–4, 55, 434, 437, 440
- infectious agents 45, 54, 128, 409–10, 413–14, 421, 428
 - human 1
- infectious disease outbreaks 12, 444
- infectious diseases 1, 3, 11, 14, 65–7, 111, 135, 173, 259, 285, 290, 411, 471, 477, 483
 - human 471
- infectivity 50, 133
- influenza 97–9, 101–4, 106–8, 111–13, 120–1, 130, 134–5, 139–44, 152, 154, 185, 282, 289, 412–13, 474–5
 - human 120, 122
- influenza A virus (IAV) 97–101, 130, 140–1, 282, 474
- influenza pandemics 99–100, 103, 106, 108, 117–18, 121, 131
- influenza segments 154–5
- influenza strains 103, 112–13
- Influenza subtypes 97, 99, 102, 107, 142, 474
- influenza virus 98, 100, 103, 107, 113–14, 120, 129–30, 133, 143, 152, 163, 282, 387, 389, 391
 - human 130
- influenza virus infection 171
- influenza watchers 106
- integrated syndromic surveillance system 1–2, 4, 6, 8, 10, 12, 14
- internal genes 116–17, 122
- internal proteins 107, 112–13, 115
- International Union of Pure and Applied Chemistry (IUPAC) 344, 460
- ion channel switch biosensor (ICSB) 185
- IPV, *see* inactivated poliovirus vaccine
- isothermal amplification technologies 411, 413, 415–17, 419
- IUPAC, *see* International Union of Pure and Applied Chemistry

- Lagos bat virus (LBV) 227–8, 230–3
- large proteins 308
- LBV, *see* Lagos bat virus
- lentiviral vectors 397, 403
- lentiviruses 397–8
- live virus 101, 242, 401
- liver 39, 132, 477–9
- low-power microwave heating 201–2, 206–7, 209, 211–12, 215–16, 220–1
- low-resource settings 409–11, 414, 417, 420–2
- lower respiratory tract infections (LRTIs) 413
- LRTIs, *see* lower respiratory tract infections
- luciferase 161–3, 402
- luminol 267, 269, 286, 350
- lyssavirus 227–8, 230, 233–5, 241
- lyssavirus antibodies 234–5, 241–2
- lyssavirus antigen 230, 232, 238, 240
- lyssavirus diagnostics 228, 233, 235–7, 239, 241
- lyssavirus infection 234–5, 240–1
- lyssavirus RNA 239–40
- lyssavirus species 228, 230–1, 235, 238, 240
- lyssavirus surveillance and diagnostics 227–8, 230, 232, 234, 236, 238, 240, 242
- lyssavirus variants 235–7
- lyssaviruses 228, 230–1, 233, 235–7, 239–40
- rabies-related 227–8, 230–1, 236, 241
- macrophages 38–9, 264–5, 271
- Madin–Darby canine kidney (MDCK) 117, 134, 400
- malaria 39, 65–6, 74–5, 118, 409, 421, 438, 483
- MAMEF, *see* microwave-accelerated metal-enhanced fluorescence
- MAMEF assay platform 212, 218–19
- MAMEF assays 210, 218–19
- MAMEF technique 206–8, 210–13, 217, 219
- Marburg hemorrhagic fever (MHF) 427, 429, 434
- Marburg virus 35, 41, 428
- matrix proteins 37–8, 112, 130, 230
- MDCK, *see* Madin–Darby canine kidney
- MEF, *see* metal-enhanced fluorescence
- meridional rays 348–9, 352
- metal-enhanced fluorescence (MEF) 201–6, 211, 213, 215, 217, 219–21
- methicillin-resistant *Staphylococcus aureus* (MRSA) 412–15
- MHF, *see* Marburg hemorrhagic fever
- microwave-accelerated metal-enhanced fluorescence (MAMEF) 206–7, 209, 211
- microwave heating 207–10, 215–20
- microwave irradiation 217–19
- MIP, *see* molecularly imprinted polymer
- MIT, *see* mouse inoculation test
- MLVs, *see* murine leukemia viruses
- Mokola virus 227
- molecularly imprinted polymer (MIP) 473
- monoclonal antibodies 133–5, 142–3, 177, 237, 301, 319
- human 50, 164

- mouse inoculation test (MIT)
240–1
- MRSA, *see* methicillin-resistant
Staphylococcus aureus
- mumps virus 131, 134
- murine leukemia viruses
(MLVs) 397, 402
- NAATs, *see* nucleic acid
amplification technologies
- NADPH oxidase 268–71
- NALF, *see* nucleic acid lateral flow
- nanobiolithography 336–7, 340
- nanolithography 335–6, 340
- nanoparticles 203–4, 458
metallic 203–4, 207
plasmonic 206, 220
- nanostructures 335, 337–8
- NASBA, *see* nucleic acid
sequence-based amplification
- NDV, *see* Newcastle disease virus
- negative-stranded RNA viruses
150–1, 157, 181
- neutralization assay 241, 400–1,
403
- neutralization-based
sero-diagnostic assay 401
- neutrophil priming 273
- neutrophils 264–7, 270, 272–4,
280, 283, 289
- Newcastle disease virus (NDV)
318, 369, 459, 482–3
- nonhuman primates 38, 51, 169
- norovirus 412–13
- novel detection techniques 149,
164
- nucleic acid amplification
technologies (NAATs)
409–10, 417, 420–2
- nucleic acid isothermal
amplification technologies
409–12, 414, 416, 418, 420,
422
- nucleic acid lateral flow (NALF)
416, 420–1
- nucleic acid sequence-based
amplification (NASBA)
411–13
- nucleic acids 141–2, 173, 310–11,
370, 399, 411, 416, 420–1,
460, 465
- nucleocapsid protein 37, 47, 49,
51, 112–13, 115, 151, 153–5,
173, 175, 237, 320, 454, 482
- nucleoprotein 112, 130, 143,
153–4, 178, 228, 230, 235
- nucleotides 23, 155, 254, 431
- oligonucleotides 344, 353, 371–2,
419, 421, 470
- optical fiber biosensors 356, 376
- optical fiber immunosensors 179,
364
- optical fibers 344–51, 353, 356,
359–61, 364, 366, 368–9,
372–4, 376
- optical transducers 344–5, 347,
349, 351
- OPV, *see* oral poliovirus vaccine
- oral poliovirus vaccine (OPV)
18–19, 21, 23, 26
- ORO fever 80–1, 83–6
- Oropouche fever 79–80, 82, 84,
86, 88, 90
- Oropouche virus 79, 81
- oxygen 266–7, 270, 464, 466
reactive 266
- oxygen metabolites 269–71
- PAMPs, *see* pathogen-associated
molecular patterns
- pandemics 97–101, 106–10,
116–17, 119–21, 130, 144,
171
human 108–9, 120

- parainfluenza 474–5
 parainfluenza virus 129
 human 49, 129
 pathogen-associated molecular
 patterns (PAMPs) 264
 pathogen detection 201–2, 204,
 206, 208, 210, 212, 214, 216,
 218, 220, 300, 410
 pathogen diagnosis 418, 421–2
 pathogenesis 38, 52, 81, 149, 157
 pathogenic viruses 454, 484
 pathogens 45, 136, 138–9, 141,
 186, 188, 201–2, 213–14, 221,
 259, 264–5, 267, 269, 413,
 418–19
 patient care 43
 patient management 66
 PCR, *see* polymerase chain reaction
 peptide phage display libraries,
 random 314
 peptides 112, 184, 266, 280,
 300–1, 307–8, 312–13, 316,
 321, 385, 460–1, 465, 469
 short 300, 314
 synthetic 469
 peroxidase 158, 267, 270–1, 478
 phage display peptides 300–1
 phage display systems 301–2,
 316–19, 321
 phage display technology 300–1,
 321
 phage DNA 302, 319
 phage genome 302, 305–6, 309
 phage particles 300, 303–6, 308,
 311, 313–14
 phage proteins 306, 315
 phages 300–4, 307–11, 313–16,
 320, 469, 477
 phagocytes 265, 267, 269, 272,
 274–5, 277, 279–83, 286, 289
 phagocytosis 265–9, 271–3, 275,
 277, 279–80, 282, 287, 289
 phagosome 265, 267–8, 270, 272,
 279
 photodetectors 362–4, 369
 plasmids 115, 154–5, 160–1, 163,
 316, 397, 400, 417
 point-of-care diagnostics 141–2,
 144
 poliomyelitis 18–19, 21, 24, 31
 poliovirus 17–26, 28, 30, 134, 153
 vaccine-derived 19, 21, 27
 wild-type 22
 poliovirus circulation 21, 30
 poliovirus transmission 20–1
 polymerase chain reaction (PCR)
 129, 136, 138–9, 159, 173,
 239, 290, 319, 333, 370, 386,
 399, 410–11, 414–15, 420–2
 polymorphonuclear leukocytes
 263, 265
 positive-stranded RNA viruses
 151, 153
 poultry 98, 102–5, 107–9, 111,
 482
 prophage 302
 protective antigen 113, 154, 218
 protein detection surface assay
 208
 protein domains 315
 proteins 81, 150–2, 213, 215, 300,
 304, 306–8, 311, 313, 315,
 317, 353–5, 358–9, 385,
 397–9
 detection of 202, 220–1
 extraction of 213
 recombinant 178, 302, 482
 structural 37–8, 132, 311
 viral 54, 130, 151, 153–5, 158,
 160, 282, 336, 388
 pseudoparticles 395–6, 399–403
 pseudotyped viruses 395–6, 398,
 400, 402
 pseudoviruses 399, 401
 pVIII capsid proteins 308, 316
 pVIII proteins 316–17

- rabies 150, 227–8, 231–2, 234–6, 240, 242
- rabies diagnosis 233, 235, 238
- rabies tissue culture infection test (RTCIT) 240
- rabies virus 227–8, 402
- RCA, *see* rolling-circle amplification
- reactive oxygen species (ROS) 265–9, 272, 274, 277, 279, 283, 287, 289
- recombinant antibodies 315
- recombinant vaccinia virus 153–4, 156
- redox mediators 466–8
- reporter gene 160–2, 396–7, 400–1
- respiratory burst 266–8, 271, 273, 277, 279–80, 287
- respiratory infections 127, 129, 131, 144, 285, 413
- acute 65, 129, 131–3
- respiratory pathogens 136, 139–40
- respiratory syncytial virus (RSV) 129–30, 134–7, 139–41, 144, 151, 282, 413
- respiratory virus detection 134
- respiratory virus panel (RVP) 140
- respiratory viruses 128–9, 131, 134–5, 137, 140–2
- retroviruses 390, 395–6
- reverse genetics 51, 116, 122, 149–50, 152–4, 156–64, 179, 396
- reverse transcriptase 173, 280, 388, 415, 417, 419
- rhinoviruses 129, 131–2
- human 139, 283
- Rift Valley fever (RVF) 41, 150–1, 367, 427–8
- RNA, viral 98, 100, 151, 235, 259, 264, 437
- RNA detection 319, 419
- RNA genome 37–8, 228, 230, 301
- RNA polymerase 101, 153, 230, 310–11, 413
- RNA transcription 411, 413–14
- rolling-circle amplification (RCA) 411, 417–18
- ROS, *see* reactive oxygen species
- ROS production 267, 269, 272–4, 277, 289
- RSV, *see* respiratory syncytial virus
- RTCIT, *see* rabies tissue culture infection test
- RVF, *see* Rift Valley fever
- RVP, *see* respiratory virus panel
- saliva 171, 187, 233–4, 240, 460
- salivary glands 234, 240
- SAM, *see* self-assembled monolayer
- SARS, *see* severe acute respiratory syndrome
- SBDSS, *see* syndrome-based disease surveillance systems
- scanning probe microscope (SPM) 337, 339–40
- SDA, *see* strand displacement amplification
- self-assembled monolayer (SAM) 337, 339, 356, 470
- sensitivity 133–6, 139, 141–4, 160–1, 164, 176–7, 180–1, 211, 235, 237–8, 257–8, 315, 318–19, 370, 372
- sensors 179–80, 182–4, 362, 370, 421, 465, 468
- serological assays 175, 403
- serotypes 20, 131–2, 139, 230
- severe acute respiratory syndrome (SARS) 2, 129, 402, 412–13
- sewage 20–1, 23, 26, 28
- sexually transmitted infections (STIs) 66–7, 74
- Shimoni bat virus 227

- shrews 229, 232, 481
 SIFs, *see* silver island films
 silane 356–7, 366
 silanization 345, 355–6, 361, 371–2
 silver 205–6, 208
 silver island films (SIFs) 205–6, 209
 silver nanoparticles 203–5, 208, 211–12
 Sin Nombre virus (SNV) 183–4, 482
 single-photon avalanche diodes (SPADs) 363–4
 SNV, *see* Sin Nombre virus
 solid-phase peptide synthesis (SPPS) 300–1
 SPADs, *see* single-photon avalanche diodes
 spillover infections 229
 SPM, *see* scanning probe microscope
 spores 202, 212, 215–19
 SPPS, *see* solid-phase peptide synthesis
 SPR, *see* surface plasmon resonance
 STIs, *see* sexually transmitted infections
 strand displacement 411, 416–19
 strand displacement activity 415–16, 418–19
 strand displacement amplification (SDA) 411–12, 418–19
 streptavidin 208, 355, 361, 370–1, 374, 459
Sudan ebolavirus 36
 supernatant 398, 400–1
 surface plasmon resonance (SPR) 179, 186, 205, 469
 syndrome-based disease surveillance systems (SBDSS) 3
 syndrome reporting information system (SYRIS) 3–14
 syndromes 4, 6, 8, 10, 67
 human 6–8
 SYRIS, *see* syndrome reporting information system
 T-cells 113, 163
 TIR, *see* total internal reflection
 TLRs, *see* toll-like receptors
 TMA, *see* transcription-mediated amplification
 TMV, *see* tobacco mosaic virus
 tobacco mosaic virus (TMV) 338
 toll-like receptors (TLRs) 264, 271–2
 transcription-mediated amplification (TMA) 411–13
 tuberculosis 65–6, 74–5, 409, 414, 419, 483
 vaccine failure 19–20
 vaccines 18, 22, 24, 29, 45, 49, 107, 115–16, 128, 172, 231, 252, 314, 454, 478
 live 27
 vaccinia virus 49, 374
 variola 118, 471
 VEEV, *see* Venezuelan equine encephalitis virus
 vegetative cells 202, 213–17, 219, 221
 vegetative organisms 216–19
 Venezuelan equine encephalitis virus (VEEV) 49
 vesicular stomatitis virus (VSV) 49–50, 151, 395, 402
 veterinarians 2, 4–6, 9, 187
 VHFs, *see* viral hemorrhagic fevers
 viral antigen 54, 158–9, 181, 234, 237, 441, 469, 479

- viral detection 129, 137, 157, 170, 177–8, 181–2, 184–5, 187, 333–4, 336, 338, 340, 454
- viral detection using amperometry 471, 473, 475, 477, 479, 481
- viral hemorrhagic fevers (VHFs) 41, 71, 173, 427, 429, 438
- viral infections 444
- viral particles 173, 304, 396–7, 399
- viral RdRp 151, 153, 155, 160
- viral respiratory diseases 127–8, 130, 132, 134, 136, 138, 140, 142
- virulent Newcastle disease virus 318
- virus antigens 175
- virus detection 54, 159–60, 213, 369, 372
- virus host cells 389
- virus isolation 83, 129, 173–4, 235, 240, 433
- virus-like particles (VLPs) 47, 398
- virus neutralization assays 241–2
- virus-neutralizing antibodies (VNAs) 234, 240–1
- virus particles 46, 99, 174, 336, 391
 - infectious 151, 160
- virus proteins 47, 173
- virus replication 39, 51, 151, 153, 234, 389
- virus strains 178, 241, 257
- viruses
 - human 100, 116
 - hypermutable 119, 122
 - infectious 41, 47, 136, 153, 177, 240–1
 - vaccine 19, 22
 - wild 20, 24, 27
- VLPs, *see* virus-like particles
- VNAs, *see* virus-neutralizing antibodies
- VSV, *see* vesicular stomatitis virus

- West Nile virus (WNV) 1–2, 71, 316, 318, 332, 365, 414, 456, 459, 476
- wild poliovirus 18–19, 23, 26, 29
- wild-type proteins 316–17
- WNV, *see* West Nile virus
- WNV antibody 477

- zymosan 271, 286